EGFR(表皮生长因子受体)
EGFR (epidermal growth factor receptor) is the cell-surface receptor of its specific ligands, including epidermal growth factor and TGFα (transforming growth factor α) and is a receptor tyrosine kinase.
- Cat.No. 产品名称 Information
-
GC25559
Lapatinib (GW-572016) Ditosylate
Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
-
GC25219
CH7233163
CH7233163 is a non-covalent ATP competitive inhibitor of EGFR-tyrosine kinase with antitumor activities against tumor with EGFR-Del19/T790M/C797S.
-
GC68440
EGFR-IN-69
-
GC68430
Selatinib
-
GC68321
O-Desmethyl gefitinib-d8
-
GC68304
Margetuximab
-
GC67860
JBJ-09-063 TFA
-
GC67759
Lapatinib-d4
-
GC67749
Amivantamab
-
GC67690
JBJ-09-063 hydrochloride
-
GC66432
EAI001
-
GC66428
EGFR-IN-5
-
GC66405
Panitumumab
Panitumumab (anti-EGFR, ABX-EGF) is a recombinant, fully human IgG2 monoclonal antibody that binds to the epidermal growth factor receptor (EGFR).
-
GC66333
Panitumumab (anti-EGFR)
-
GC65992
FGFR2-IN-3
-
GC65991
FGFR2-IN-3 hydrochloride
-
GC65974
EGFR-IN-9
-
GC65572
EGFR Protein Tyrosine Kinase Substrate
-
GC65436
JND3229
JND3229 is a potent reversible inhibitor of EGFRC797S with an IC50 value of 5.8 nM. JND3229 also potently suppresses EGFRL858R/T790M and EGFRWT with IC50 values of 30.5 nM and 6.8 nM, respectively.
-
GC65310
TAS0728
A covalent HER2 inhibitor
-
GC64770
Oritinib
-
GC64710
MC-Val-Cit-PAB-Amide-TLR7 agonist 4
-
GC64497
EGFR-IN-17
-
GC64398
Almonertinib mesylate
-
GC64302
BAY 2476568
-
GC64039
Disitamab vedotin
-
GC64017
Befotertinib
-
GC63910
BLU-945
BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor(EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC).
-
GC63797
(S)-Sunvozertinib
DZD9008 (Sunvozertinib) is an oral, potent, irreversible, wild type-selective EGFR inhibitor against EGFR or HER2 Exon20ins and other mutations with IC50 ranging from 0.4 nM to 2.1 nM for mutant EGFR.
-
GC63521
Sunvozertinib
-
GC62958
Erlotinib-13C6
-
GC62632
JBJ-04-125-02
-
GC62601
Nimotuzumab
-
GC62569
DBPR112
-
GC62562
EGFR-IN-11
-
GC62481
AST5902 trimesylate
AST5902 is the principal metabolite of alflutinib both in vitro and in vivo, which exerts remarkable antineoplastic activity similar to alflutinib. AST5902 exhibits much weak CYP3A4 induction potential compared to alflutinib.
-
GC62420
EMI56
-
GC62402
ASK120067
-
GC62385
Simotinib
-
GC62384
Epitinib succinate
-
GC62341
Rezivertinib
-
GC62160
Mobocertinib succinate
An inhibitor of mutant EGFR and HER2 receptors
-
GC62159
Tucatinib hemiethanolate
An inhibitor of HER2
-
GC61807
(E/Z)-AG490
-
GC61780
SU5204
SU5204 is a tyrosine kinase inhibitor with IC50 of 4 μM and 51.5 μM for FLK-1 (VEGFR-2) and HER2, respectively.
-
GC61490
Trastuzumab emtansine
Trastuzumab Emtansine(T-DM1,Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1.Trastuzumab emtansine has a molecular weight of 145kDa.
-
GC61473
Trastuzumab deruxtecan
Trastuzumab deruxtecan (DS-8201a, T-DXd, DS-8201) is an antibody-drug conjugate (ADC) composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody and a cytotoxic topoisomerase I inhibitor. Trastuzumab deruxtecan shows durable antitumor activity. Trastuzumab deruxtecan has a molecular weight of 153KDa.
-
GC50706
JBJ-03-142-02
Highly potent epidermal growth factor receptor (EGFR) and ErbB2 (human epidermal growth factor receptor; HER2) inhibitor
-
GC47303
Erlotinib-d6 (hydrochloride)
An internal standard for the quantification of erlotinib
-
GC61161
Osimertinib D6